BRUKINSA® (zanubrutinib) is a Bruton’s kinase inhibitor indicated for the treatment of adult patients with:

  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
  • Waldenström’s macroglobulinemia (WM)
  • Mantle cell lymphoma (MCL) who have received at least one prior therapy
  • Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen

The MCL and MZL indications are approved under accelerated approval based on overall response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.


Zanubrutinib (BRUKINSA®) is a National Comprehensive Cancer Network® (NCCN®) preferred treatment option for patients with CLL3:

Without del(17p)/TP53
First-line: Category 1
Second-line: Category 1

With del(17p)/TP53
First-line: Category 2A
Second-line: Category 1

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 7, 2023. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guidelines, go online to